Summaries of Review for Applications to RFA 09-01
The following is a listing of all applications reviewed under RFA 09-01 for CIRM Disease Team Research Awards. Applications include the score (between 0 and 100, with 100 being the best) and a funding recommendation (indicated by the color key below) made by the Grants Working Group (GWG) during the review meeting on September 9-11, 2009. A link to the Public Abstract (provided by applicant), Statement of Benefit to California (provided by applicant), and Public Review Report are available for each application by clicking on the respective application number.
|
|
= Recommended for funding |
|
= Not Recommended for funding at this time |
| Application Number | ICOC decision | Title | Scientific Score |
|---|---|---|---|
| DR1-01490 | Approved | Zinc Finger Nuclease-Based Stem Cell Therapy for AIDS | 90 |
| DR1-01423 | Approved | Cell Therapy for Diabetes | 85 |
| DR1-01452 | Approved | Stem Cell Gene Therapy for Sickle Cell Disease | 82 |
| DR1-01430 | Approved | Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) | 81 |
| DR1-01431 | Approved | HPSC based therapy for HIV disease using RNAi to CCR5. | 79 |
| DR1-01471 | Approved | Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis | 78 |
| DR1-01461 | Approved | Autologous cardiac-derived cells for advanced ischemic cardiomyopathy | 75 |
| DR1-01426 | Approved | Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) | 72 |
| DR1-01444 | Approved | Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) | 72 |
| DR1-01454 | Approved | iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa | 70 |
| DR1-01477 | Approved | Therapeutic Opportunities to Target Tumor Initiating Cells in Solid Tumors | 70 |
| DR1-01480 | Approved | Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke | - |
| DR1-01485 | Approved | Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells | - |
| DR1-01422 | - | CNS Derived Stem Cells for the Treatment of Thoracic and Cervical Spinal Cord Injury | - |
| DR1-01459 | - | Directed differentiation of MSCs by a novel biologic to promote cartilage repair | - |
| DR1-01487 | - | Stem Cell-Based Targeted Immune Therapy for Cancer | - |
| DR1-01450 | - | U.S./CFP Airway Team: Tissue Engineered Airways for Children with Tracheal Obstruction | - |
| DR1-01491 | - | Develop a cell replacement therapy for Parkinson's disease using human embryonic stem cells | - |
| DR1-01467 | - | Targeting nanotherapeutics against acute leukemia stem cells | - |
| DR1-01492 | - | Liver Disease Team | - |
| DR1-01482 | - | Autologous Delivery of Pim-1 Enhanced Cardiac Stem Cells: A Novel Clinical Therapy for Cardiac Muscle Regeneration Post MI | - |
| DR1-01460 | - | Stem Cells for Treating Pre-Arthritic Focal Cartilage Defects | - |
| DR1-01458 | - | Pre-Clinical Development of Stem Cell-Based Replacement Therapies for Stroke | - |
| DR1-01478 | - | Using Nell-1 to harness the osteogenic potential of adult stem cells | - |
| DR1-01421 | Approved | Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials | - |
| DR1-01476 | - | Hematopoietic Stem Cell Transplants for Severe Combined Immune Deficiency and Systemic Sclerosis | - |
| DR1-01451 | - | Stem Cells for Neuroprotection of Photoreceptors in Retinitis Pigmentosa | - |
| DR1-01486 | - | Stem cell therapies for Huntington's Disease and other neurodegenerative disorders | - |
| DR1-01453 | - | WALQ team for saving limbs and keeping Californians on their feet | - |
| DR1-01446 | - | Human Spinal Cord Neural Stem Cells for Treatment of Acute Traumatic Spinal Cord Injury | - |
| DR1-01449 | - | hESC-Derived Motor Neuron Progenitors for the Treatment of Spinal Muscular Atrophy | - |
